By Chris Wack

 

Altimmune Inc. said Friday it expanded its previously announced AdCOVID manufacturing collaboration with Lonza.

Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune's single-dose intranasal vaccine candidate for Covid-19, at its facility near Houston.

The biopharmaceutical company said that by expanding its Lonza collaboration and commissioning its own dedicated manufacturing suite, it is building extra capacity and redundancy into its manufacturing to support potential late-stage clinical trials with AdCOVID and potential future commercial supply.

AdCOVID is a Covid-19 vaccine candidate that is administered via nasal spray. Altimmune believes that AdCOVID could provide immunity of up to a year or more following a single dose with the potential for a favorable tolerability profile. AdCOVID is expected to be shipped without cold chain logistics, permitting common refrigerated storage at community-based vaccination centers without the need for specialized freezer storage.

Altimmune's shares rose 20% to $20.06 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

March 12, 2021 06:29 ET (11:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.